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Patients diagnosed with tuberculosis at death or who died 
during therapy: association with the human immunodeficiency 
virus
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SUMMARY
OBJECTIVES—To describe trends and risk factors for tuberculosis (TB) mortality.
DESIGN—We calculated trends, identified patient characteristics associated with TB diagnosis at 
death or death during TB treatment, and described diagnostic procedures using the United States 
National TB Surveillance System for 1997–2005.
RESULTS—Human immunodeficiency virus (HIV) infected TB patients had an adjusted odds 
ratio (aOR) of 4–11 for TB diagnosis at death (foreign-born non-Whites, aOR = 11) and of 3–19 
for death during TB treatment vs. non-HIV-infected patients. Odds increased by age. Hispanic 
males had an aOR of 2 for TB diagnosis at death compared with female non-Hispanics. 
Multidrug-resistant TB (MDR-TB) patients had a three times greater aOR of death during 
treatment than non-MDR patients. American Indians, Black females, residents in long-term care 
facilities, US-born patients, and non-HIV-infected homeless persons aged 25–44 years each had an 
aOR of 2 for mortality during treatment; 86% of pulmonary patients diagnosed at death had a 
chest radiograph, but 34% had no sputum smear or culture reported.
CONCLUSION—During 1997–2005, controlling for age, HIV remained the characteristic with 
the greatest aOR for TB diagnosis at death or death during TB therapy. Race/ethnicity, country of 
birth and homelessness further increased the adjusted odds of death. Results show possible missed 
opportunities for TB diagnosis prior to death.
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TUBERCULOSIS (TB) remains a potentially deadly disease, especially for those living with 
human immunodeficiency virus (HIV) infection. Deaths can occur prior to TB diagnosis or 
during TB treatment.
The most recent publication on TB mortality (diagnosis at death) using the United States 
National TB Surveillance System (NTSS) was in 1991, before HIV infection was reported in 
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TB case reports.1 Using 1985–1988 NTSS data, the authors found that 5.1% (4373) of TB 
patients were diagnosed at death. From a multivariate model, the adjusted odds ratio (aOR) 
of being diagnosed with TB at death increased with age (34–54 years, aOR 1.4–1.5; 55–64 
years, aOR 2.5; 65–74 years, aOR 4.0; 75–84 years, aOR 6.5; ≥85 years, aOR 11.3), being 
Black (aOR 1.3) or Hispanic (aOR 1.2), and having miliary, meningeal, or peritoneal TB 
(aOR 4.7–5.7).
A clinical trial of TB patients enrolled after 2 months of treatment during 1995–1998 found 
that 7% died during therapy or during the 2-year follow-up; those who died (vs. those who 
survived) were more likely to have malignancy (aOR 5.3), to be HIV-infected (aOR 3.9), to 
use alcohol daily (aOR 2.9), to be unemployed (aOR 2.0), and to be older (aOR 1.1).2 
Several studies document that HIV-infected TB patients on antiretroviral therapy (ART) 
during TB therapy survive for longer than those not on ART.3–7
The present study describes trends in mortality and characteristics associated with TB 
diagnosis at death or death during TB therapy. We also describe diagnostic procedures for 
patients diagnosed at death to assess missed opportunities for prevention.
METHODS
In the NTSS, there are two mortality outcomes associated with TB: 1) TB diagnosis at 
death; and 2) death during TB treatment. A diagnosis of TB at death is defined as when TB 
is investigated after a patient dies, or if a live patient on one or less anti-tuberculosis 
medication died and is subsequently diagnosed with TB disease. If a patient was suspected 
or diagnosed with TB disease and started on two or more anti-tuberculosis medications, then 
dies during TB treatment, this is classified as death during TB treatment.
We excluded data from California, which has not reported AIDS (acquired immune-
deficiency syndrome) registry match data for TB patients to the Centers for Disease Control 
and Prevention (CDC) since 2004, and data for patients with unknown (as positive or 
negative) HIV status. In 2004, California reported 123 TB patients with AIDS, i.e., 10% of 
known TB-HIV patients in the United States. Since 1989, the CDC has recommended that 
all TB patients be offered HIV testing.8 Reporting of the HIV status of TB patients to the 
CDC began in 1993, and has increased over time from 54% of patients in 1997 to 71% in 
2005 (excluding California; unpublished analyses by Elvin Magee).
We separately analyzed TB diagnoses at death and deaths during TB treatment from the 
NTSS for 1997–2005,* a period when access to highly active ART (HAART) became 
available to many persons living with HIV infection. We described trends in mortality data 
and case-fatality rates (CFR; i.e., deaths divided by TB cases) by race/ethnicity and for TB-
HIV. We identified characteristics associated with mortality outcomes by comparing dead vs. 
alive TB patients. We performed bivariate analyses and then multivariate logistic regression 
using backwards selection to obtain aORs at the 99% confidence level. The following 
variables were entered into both multivariate models: age (0–4, 5–14, 25–44, 45–64, 65–74, 
*NTSS dataset as of May 9, 2009.
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70–74, 75–79, 80–84, ≥85 years; 15–24 as referent), race/ethnicity (White, Black/African 
American, Hispanic, American Indian/Alaskan native; Asian as referent), sex (male, female 
as referent), country of birth (US, foreign-born as referent), HIV infection (HIV-positive, 
HIV-negative as referent) and multidrug-resistant TB (MDR-TB; isoniazid and rifampin 
resistance on initial or final drug susceptibility tests, otherwise as referent). For deaths 
during treatment, the following additional variables were entered: homelessness (yes within 
past year, otherwise as referent), injecting drug use (yes within past year, otherwise as 
referent), non-injecting drug use (yes within past year, otherwise as referent), excess alcohol 
use (yes within past year, otherwise as referent), incarceration (prison/jail resident at time of 
diagnosis, otherwise as referent), and long-term care residency (resident at time of diagnosis, 
otherwise as referent). Interaction was assessed among all variables identified by backwards 
selection in each model, with significant interaction terms and their components retained.
We described reported diagnostic procedures separately for pulmonary and extra-pulmonary 
only TB cases diagnosed at death. Similar analyses were then conducted to assess reported 
diagnostic methods.
US state and local health departments report TB cases to the NTSS under an assurance of 
confidentiality; this analysis has been cleared by the CDC for public release.
RESULTS
Trends
During 1997–2005, among 146 253 US-reported TB cases, 3770 cases were diagnosed at 
death and 10 989 died during treatment. Mortality declined by 9% annually during 1997–
2005, over twice the 4% average annual decline in total TB cases. However, TB diagnosed at 
death declined by only 1% in 2003 from 2002, and increased in 2005 from 2004.
In 2005, as a percentage of total reported TB cases, 2.1% of TB patients were diagnosed at 
death and 5.8% died during TB treatment (Figure 1). CFRs were highest during 1997–2005 
for Whites, followed by Blacks, Hispanics, and Asians (Figure 2). Average annual CFR 
declines were similar for Whites, Blacks, and Hispanics, at 5–6% for TB diagnoses at death 
and 4–6% for deaths during TB treatment. For Asians, CFR on diagnosis at death increased 
in 2004 and 2005, while the CFR for death during TB treatment increased in 2005.
Excluding California and cases with unknown HIV status, HIV-infected patients comprised 
49% of diagnoses at death and 38% of deaths during treatment in 1997–2005, declining to 
respectively 34% and 31% in 2005. Deaths during treatment ranged from 17% of HIV-
infected TB patients in 1997 to 13% in 2005. For diagnoses at death, TB-HIV CFRs ranged 
from 4% in 1997 to 2% in 2005. CFRs for persons with HIV infection declined linearly 
during 1997–2005, with deaths during treatment falling by 0.4% annually (R2 = 0.52) and 
diagnoses at death by 0.2% annually (R2 = 0.53).
Characteristics associated with TB mortality in multivariate analyses
After exclusion of California and cases with unknown HIV, 950 cases of TB were diagnosed 
at death and 4578 died during TB treatment from 1997 to 2005. Mortality outcomes 
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increased with age. For TB diagnosed at death, controlling for age, HIV-infected persons 
aged 25–44 years, foreign born and non-Whites had the greatest odds (aOR 11.4), followed 
by age 25–44 years, US-born Whites (aOR 9.5), non-White foreign-born patients aged <25 
or ≥45 years (aOR 7.3), White US-born aged <25 or ≥45 years (aOR 6.0), non-White US-
born aged 25–44 years (aOR 5.7), and US-born non-Whites aged <25 or ≥45 years (aOR 
3.6; Table 1).
For deaths during TB treatment, HIV-infected persons who were non-homeless and aged 45–
64 years had the greatest odds (aOR 18.9), followed by the homeless aged 25–44 years (aOR 
8.5), non-homeless aged 25–44 (aOR 7.7), homeless aged <25 or ≥65 years (aOR 3.9), non-
homeless aged <25 or ≥45 years (aOR 3.6), and homeless patients aged 45–64 years (aOR 
3.0; Table 2).
Hispanic males diagnosed with TB at death had an aOR 2.3 times greater than female 
Asians (Table 1). Patients with MDR-TB had an aOR for death during treatment 2.7 times 
greater than non-MDR patients (Table 2). American Indians, Black females, residents in 
long-term care facilities, US-born patients, and non-HIV-infected homeless persons aged 
25–44 years each had an aOR of 2 for mortality during treatment. Non-Black males, 
Hispanics, and Whites had increased aORs (respectively 50%, 50% and 40%) compared 
with those without these characteristics.
Reported TB diagnostic practices of patients diagnosed with TB at death
For pulmonary TB patients diagnosed with TB at death (n = 668), 29% (n = 196) reported a 
tuberculin skin test (TST), compared with 78% of live patients; 86% (n = 574) reported a 
chest radiograph (CXR), of which 94% (n = 540) were abnormal (Figure 3). Over one third 
(n = 230, 34%) reported no sputum smear/culture for acid-fast bacilli (AFB), including 173 
who had a CXR; 9% (n = 57) reported neither a CXR nor a sputum smear. Reported sputum 
smears were less likely to be AFB-positive among those diagnosed with TB at death than for 
live TB patients (P < 0.05).
For extra-pulmonary only TB patients who were dead at diagnosis (n = 282), 30% (n = 85) 
reported a TST vs. 76% of those alive; 86% (n = 243) reported a CXR, of which 70% were 
abnormal (n = 170), and 72% (n = 204) had a specimen other than sputum examined.
The main sites of disease for those dead (vs. alive) at TB diagnosis were pulmonary (69% 
vs. 78%), pleural (4% vs. 4%), miliary (9% vs. 2%), meningeal (7% vs. 1%), peritoneal (2% 
vs. 1%) and other (6% vs. 2%). Specimens other than sputum taken from lung, cerebrospinal 
fluid, blood and feces were more likely to be AFB-positive.
DISCUSSION
TB-associated mortality reflects both the risk of death with undiagnosed TB or during TB 
treatment and the risk of a diagnosis of TB after death. Patients who are older or have 
comorbidities such as HIV have a greater overall risk of death, regardless of their TB 
disease.9,10 However, some proportion of these deaths is caused by TB and might be 
preventable.
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The study findings highlight groups that should be targeted for reducing TB-associated 
mortality. TB-HIV cases comprised 40–50% of TB mortality from 1997 to 2005. While TB-
HIV mortality declined linearly over the period, HIV infection remained the strongest 
associated factor, controlling for older age. HIV-infected TB patients had an aOR of 4–11 
for TB diagnosis at death (foreign-born non-Whites aOR = 11) and of 3–19 for death during 
TB treatment versus non-HIV-infected patients. In addition to preventing TB and associated 
mortality through latent TB infection (LTBI) treatment among HIV-infected persons, 
HAART can reduce TB incidence,11–13 recurrence with disease (i.e., another instance of TB 
disease following treatment completion) and mortality.3
Other groups disproportionately experiencing TB-associated mortality during 1997–2005 
included MDR-TB patients, American Indians, males, Black females, long-term care 
residents, homeless non-HIV-infected persons, Hispanics and Whites. TB CFRs fell for 
Whites, Blacks and Hispanics during 1997–2005, indicating progress in reducing mortality 
relative to TB cases. However, Asian patients (overwhelmingly foreign-born) did not 
experience declining CFR trends. Delays in TB diagnosis associated with lack of access to 
care, the severity/toxicity of MDR-TB, and co-morbidities undocumented in the NTSS (e.g., 
cancer) likely explain some of these disparities.
The risk of a TB diagnosis at death depends on access to care, diagnostic practices and the 
sensitivity of TB diagnostics. Reported diagnostic practices for patients diagnosed with TB 
at death suggest that 86% of both pulmonary and extra-pulmonary TB patients entered some 
health care facility while alive and had a CXR. The patients likely had some evidence of 
pulmonary disease prior to death for which a CXR was performed (possibly to detect 
pneumonia, a common and deadly disease). One third of pulmonary patients had no sputum 
smears/cultures reported, which are generally ordered if the physician suspects TB. For HIV-
infected patients during the study period, the CDC recommended both CXRs and sputum 
examinations (regardless of the CXR result).14 In 2009, the CDC recommended a CXR and 
sputum smear with culture only for patients with pulmonary symptoms and CXR 
abnormalities.15 Missing sputum smear reports could be due to: 1) late CXR readings, 
available after death, resulting in no smear ordered; 2) non-suspicion of TB, and thus no 
smear ordered; or 3) non-reporting of sputum smear results. For extra-pulmonary only TB 
cases diagnosed at death, 28% had no result reported other than for sputum. Diagnostic 
algorithms need to be improved to identify TB disease more rapidly and assess diagnostic 
reporting.
Lack of TB detection using current diagnostic techniques, which have low sensitivity for 
immunosuppressed patients, can delay TB diagnosis and care, leading to mortality. Among 
HIV-infected TB patients, extra-pulmonary disease is more common, and among pulmonary 
patients the sputum smear is often falsely negative, with only culture showing the 
Mycobacterium tuberculosis organism. In HIV-infected immunosuppressed persons, CXRs 
are often normal. One fourth of HIV-infected persons with pulmonary TB disease have false-
negative TST or interferon-gamma release assay results, showing that LTBI diagnostic tests 
cannot be relied upon to exclude TB disease.16 Early knowledge of HIV infection through 
routine HIV testing of TB suspects and contacts might alert providers to screen for TB 
disease using all available tools.
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Because of small numbers, we did not analyze data separately for native Hawaiians. For the 
TB diagnosis at death analyses, some factors could not be examined for those who died 
because of significantly more missing data on injecting and non-injecting drug use, excess 
alcohol use, homelessness, residence in a long-term care facility and residence in a 
correctional facility. The following patients were more likely to be missing HIV status: those 
aged ≥65 years, Whites, American Indians, Asians, US-born, long-term care residents and 
those with extra-pulmonary TB. While some of these patients are known to have lower rates 
of HIV infection (e.g., ≥65 years, Whites, Asians), others (e.g., US-born, extra-pulmonary 
cases) have higher rates. The exclusion of US-born and extra-pulmonary cases with 
unknown HIV status might therefore have resulted in the underestimation of the odds of TB 
mortality for these patients. Another limitation was that the NTSS did not assess 
comorbidities other than HIV and did not collect data on HAART use during the study 
period.
TB as a cause of death is difficult to ascertain and cannot be determined definitively from 
the NTSS. Autopsies declined from 41% of hospital deaths in 1961 to 5–10% in the 
mid-1990s in the United States.17,18 In the absence of US autopsy studies, one US study 
using smears at death and tissue cultures found that 22% of a 1997 TB-HIV cohort died, 
44% of which were from TB.7 A random sample (n = 20) record review of the cause of TB-
associated deaths during 2000–2004 in California found that 85% (n = 17) were definitely or 
possibly TB-related and that 60% (n = 12) could have been prevented; death certificate data 
were often inaccurate in determining the cause of death.19 Reviews of medical records and 
other data, in the absence of autopsies, could improve the determination of the cause of TB-
associated mortalities,19 and improve the completeness of data on excess alcohol use, 
injecting drug use, non-injecting drug use, homelessness, and residence in a long-term care 
facility or correctional facility. In 2009, the NTSS began collecting TB as a cause of death 
and comorbidities (diabetes, immunosuppression, end-stage renal disease). The CDC is 
currently conducting a national study on TB mortality.
CONCLUSIONS
While TB mortality in HIV-infected persons has declined over time due to reductions in TB 
incidence and prevalence, the implementation of HAART, and improvements in TB and HIV 
case management in the United States,20 HIV-infected TB patients still had a 3–19 times 
higher adjusted odds of TB-associated mortality than non-HIV-infected TB patients. We 
need to increase routine voluntary HIV testing of TB contacts and TB suspects and provide 
HAART, routinely screen known HIV-infected persons for TB symptoms, target LTBI and 
TB testing for populations experiencing mortality disparities, and improve TB diagnostics 
and diagnostic algorithms to prevent TB-associated mortality.
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TB-associated mortality, number and percentage of cases. A. TB diagnosed at death, NTSS, 
1997–2005. B. Death during TB treatment, NTSS, 1997–2005. TB = tuberculosis; NTSS = 
United States National TB Surveillance System.
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A. Case-fatality rates for TB diagnosed at death by race/ethnicity. Rates not shown for native 
Hawaiians (range 0–4.7, average = 2.7). B. Case-fatality rates for death during TB treatment 
by race/ethnicity. Rates not shown for native Hawaiians (range 0–9.6, average = 4.8). NH = 
native Hawaiians; AIAN = American Indian/Alaskan native.
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Reported diagnostics of pulmonary and extra-pulmonary TB cases. A. Reported diagnostics 
of pulmonary TB cases. B. Reported diagnostics of extra-pulmonary TB cases. CXR = chest 
X-ray; exam = examination; TB = tuberculosis.
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Table 1
Characteristics associated with tuberculosis diagnosed at death (n = 950)
Characteristic n Adjusted OR (99%CI)
Age ≥85 years 36 16.2 (8.0–33.2)
Age 80–84 years 38 13.1 (6.5–26.4)
HIV-infected, age 25–44 years, non-White, foreign-born 69 11.4 (5.6–23.2)
Age 75–79 years 46 10.7 (5.4–21.1)
Age 70–74 years 49 9.5 (4.8–18.5)
HIV-infected, age 25–44 years, White, US-born 30 9.5 (3.2–28.3)
HIV-infected, non-age 25–44 years, non-White, foreign-born 36 7.3 (4.7–11.1)
Age 65–69 years 49 7.2 (3.7–14.1)
HIV-infected, non-age 25–44 years, White, US-born 24 6.0 (2.4–15.4)
HIV-infected, age 25–44 years, non-White, US-born 179 5.7 (2.1–15.2)
Age 45–64 years 326 4.1 (2.3–7.3)
HIV-infected, non-age 25–44 years, non-White, US-born 118 3.6 (1.6–8.1)
Hispanic male 123 2.3 (1.1–4.8)
Non-Hispanic male 571 1.1 (0.9–1.3)
Hispanic female 19 0.5 (0.3–0.9)
OR = odds ratio; CI = confidence interval; HIV = human immunodeficiency virus.
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Table 2
Characteristics associated with death during tuberculosis treatment (n = 4578)
Characteristic n Adjusted OR (99%CI)
Age ≥85 years 248 26.4 (19.2–36.3)
HIV-infected, age 45–64 years, non-homeless 554 18.9 (14.1–25.2)
Age 80–84 years 239 18.6 (13.5–25.4)
Age 75–79 years 308 16.0 (11.9–21.6)
Age 70–74 years 302 13.1 (9.7–17.6)
Age 65–69 years 316 10.6 (7.9–14.2)
HIV-infected, age 25–44 years, homeless 114 8.5 (5.9–12.2)
HIV-infected, age 25–44 years, non-homeless 854 7.7 (5.7–10.4)
Age 45–64 years, no HIV, non-homeless 948 5.3 (4.1–6.8)
HIV-infected, non-age 25–64 years, homeless 233 3.9 (3.1–5.0)
HIV-infected, non-age 25–44 years, non-homeless 679 3.6 (3.1–4.1)
HIV-infected, age 45–64 years, homeless 101 3.0 (1.9–4.8)
MDR-TB 102 2.7 (2.0–3.6)
American Indian 81 2.4 (1.7–3.5)
Black females 761 2.1 (1.6–2.6)
Long-term care residents 278 1.9 (1.5–2.2)
US-born 3645 1.8 (1.6–2.0)
Homeless, no HIV, age 25–44 years 55 1.7 (1.2–2.4)
Non-Black males 1675 1.5 (1.3–1.7)
Age 25–44 years, no HIV, non-homeless 304 1.5 (1.2–2)
Hispanic 722 1.5 (1.2–1.9)
White 1150 1.4 (1.1–1.7)
Correctional facility resident 151 0.7 (0.6–0.9)
OR = odds ratio; CI = confidence interval; HIV = human immunodeficiency virus; MDR-TB = multidrug-resistant tuberculosis.
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